Company: NIVFW
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001213900-25-033966
Chunk: 34

Company: NewGenIvf Group Ltd
Filing Date: 2025-04-22
Form: 20-F
Item: Item 3
Chunk 34
---
) potential prohibition on surrogacy or providing intermediary assistance in surrogacy; and (viii) licensing and
approval of the accommodation provided as parts of the services.

NewGenIvf has attempted to
structure its operations to comply with laws, regulations and other requirements applicable to it directly and to its clients and vendors,
but there can be no assurance that its operations will not be challenged or impacted by regulatory authorities or enforcement initiatives,
or that the relevant authorities in each jurisdiction could impose higher standards or requirements, which NewGenIvf may have difficulty
to adhere to, e. g. Medical Facilities Act B. E. 2541 (1998) and Protection of a Child Born by Medically Assisted Reproductive Technology
Act B. E. 2558 (2015) for Thailand jurisdiction, Law on Reproduction Rights and on Guarantees of Their Realization of July 4,
2015 No. 148, Law on status of medical worker of May 28, 2013 No. 81 and Temporary Regulation on Procedure of Licensing Private Medical
Activity approved by the resolution of government of April 4, 2017 No. 203 for Kyrgyz Republic. NewGenIvf in the future may become
involved in governmental investigations, audits, reviews and assessments. Any determination by a court or agency that NewGenIvf’s
solutions or services violate, or cause its clients to violate, applicable laws, regulations or other requirements could subject it or
its clients to civil, criminal, or administrative penalties. Such a determination also could require it to change or terminate portions
of its business, disqualify it from serving clients that do business with government entities, or cause it to refund some or all of its
service fees or otherwise compensate its clients. In addition, failure to satisfy laws, regulations or other requirements could adversely
affect demand for its solutions and could force it to expend significant capital, research and development and other resources to address
the failure. Even an unsuccessful challenge by regulatory and other authorities or parties could be expensive and time-consuming, could
result in loss of business, exposure to adverse publicity, and injury to its reputation and could adversely affect its ability to retain
and attract clients. If NewGenIvf fails to comply with applicable laws, regulations and other requirements, its business, financial condition
and results of operations could be adversely affected. Such non-compliance could also require significant investment to address and may
prove costly. There are several additional state statutes